Phobia, Social
7
1
1
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
14.3%
1 terminated out of 7 trials
83.3%
-3.2% vs benchmark
29%
2 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (7)
Investigating the Effects of Cannabidiol on Social Anxiety Disorder
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
Combined CBM For Social Anxiety in Turkey
Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders
Gaze Contingent Feedback in Social Anxiety Disorder
Dysfunctional Attention Processes in Fear of Blushing: Specificity and Changeability
Internet Treatment for Social Phobia in Romania